Skip to main content

Table 1 Clinical, enzymatic, and molecular information of 27 Chinese patients w ith late-onset Pompe disease

From: Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation

No.

Gender/Age

Age of onset(years)

Age of diagnosis (years)

Initial symptoms

Family history

CK(IU/L)

Muscle pathology

lymphocyteGAA activity (pmol/punch/hr) 1

GAA gene mutation

Requirement of ventilator support

Allele1

Allele2

1

F/3

1.2

3

Muscle weakness

No

568

Vacuolar myopathy

ND

c.503G > A

c.2237G > A

Yes

2

F/3.5

2

3.5

Muscle weakness and adynamia in swallowing

No

700

Vacuolar myopathy

ND

c.503G > C

c.1082C > T

No

3

M/14

8

14

Muscle weakness

No

907

Vacuolar myopathy

ND

c.796C > T

c.1309C > T

No

4

F/22

5

22

Muscle weakness

No

1101

Vacuolar myopathy

ND

c.1562A > T

c.1781G > A

No

5

M/30

10

30

Muscle weakness

No

642

Vacuolar myopathy

ND

c.503G > A

c.2237G > A

No

6

F/23

21

21

Limb girdle weakness

No

1047

ND

0

c.1355delC

c.2238G > C

Yes

7

M/17

17

17

Muscle weakness

No

1413

ND

ND

c.2238G > C

c.2238G > C

No

8

M/12

12

12

Muscle weakness

No

1365

Vacuolar myopathy

3.15

c.871C > T

c.2238G > C

No

9

M/23

21

21

Limb girdle weakness

No

2391.6

ND

2.25

c.323G > A

c.2014C > T

No

10

M/14

6

13

Respiratory insufficiency

No

637

Vacuolar myopathy

3.96

c.1935C > A

c.2238G > C

No

11

F/17

3

4

High level of serum CK

No

1227

Vacuolar myopathy

0.25

c.2238G > C

c.2662G > T

No

12

F/15

10

13

Limb girdle weakness

No

ND

Vacuolar Myopathy

4.04

c.2238G > C

 

No

13

F/24

12

20

Muscle weakness

No

1200

Vacuolar myopathy

1.15

c.1561G > A

c.2161G > T

Yes

14

F/25

15

23

Muscle weakness

No

662.6

Vacuolar myopathy

ND

c.1315_1317delATG

c.2238G > C

Yes

15

F/35

29

35

Muscle weakness

No

406

Vacuolar myopathy

3.54

c.1082C > T

 

No

16

F/33

32

32

High level of serum CK

No

927

Vacuolar myopathy

3.32

c.-32-13 T > G

c.2662G > T

No

17

M/32

28

32

Muscle weakness

No

117

Vacuolar myopathy

8.05

c.1634C > T

c.2662G > T

No

18

F/35

25

25

Sleep disordered breathing

No

79

Vacuolar myopathy

ND

c.2238G > C

c.2431delC

Yes

19

M/20

19

20

Limb girdle weakness

No

800

Vacuolar myopathy

3.46

c.1634C > T

c.1993G > A

Yes

20

F/23

23

23

Respiratory insufficiency

No

345

Vacuolar myopathy

5.98

c.1551 + 3_c.1551 + 6delAAGT

c.2238G > C

Yes

21

F/32

23

30

Muscle weakness

No

139

Vacuolar myopathy

1.1

c.1935C > A

c.2238G > C

Yes

22

F/14

9

14

Limb girdle weakness

No

970

Vacuolar myopathy

ND

c.2446G > A

c.2662G > T

No

232

F/30

24

30

Muscle weakness

Yes

563

ND

ND

c.1396delG

c.2238G > C

No

242

F/28

23

28

Muscle weakness

Yes

746

ND

ND

c.1396delG

c.2238G > C

No

253

M/24

16

22

respiratory insufficiency and fatigue

Yes

790

ND

0

c.241C > T

c.2238G > C

Yes

263

F/31

12

28

Muscle weakness

Yes

ND

ND

0.6

c.241C > T

c.2238G > C

No

273

F/29

27

27

Limb girdle and muscle weakness

Yes

303

ND

0.44

c.241C > T

c.2238G > C

Yes

  1. 1 The median activities of 19 normal controls and 14 carriers were 36.37(range, 15.16–297.86) and 24.77 (range, 11.84–43.97) pmol/punch/hour, respectively.
  2. 2 patient 23 and 24 are siblings; 3 patient 25, 26, 27 are siblings.